Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.

Araujo RL, Gaujoux S, Huguet F, Gonen M, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Jarnagin WR, Goodman KA, Allen PJ.

HPB (Oxford). 2013 Aug;15(8):574-80. doi: 10.1111/hpb.12033. Epub 2013 Jan 10.

2.

Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.

Denost Q, Laurent C, Adam JP, Capdepont M, Vendrely V, Collet D, Cunha AS.

HPB (Oxford). 2013 Sep;15(9):716-23. doi: 10.1111/hpb.12039. Epub 2013 Jan 10.

3.

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B.

Radiother Oncol. 2014 Oct;113(1):41-6. doi: 10.1016/j.radonc.2014.09.010. Epub 2014 Oct 15.

4.

Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.

Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2012 May;19(5):1663-9. doi: 10.1245/s10434-011-2156-7. Epub 2011 Dec 1.

PMID:
22130621
5.

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.

Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, Groothuis KB, Busch OR, Besselink MG, de Hingh IH, Ten Tije AJ, Patijn GA, Bonsing BA, de Vos-Geelen J, Klaase JM, Festen S, Boerma D, Erdmann JI, Molenaar IQ, van der Harst E, van der Kolk MB, Rasch CR, van Tienhoven G; Dutch Pancreatic Cancer Group (DPCG).

Trials. 2016 Mar 9;17(1):127. doi: 10.1186/s13063-016-1262-z.

6.

Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.

Kwon D, McFarland K, Velanovich V, Martin RC 2nd.

Surgery. 2014 Oct;156(4):910-20. doi: 10.1016/j.surg.2014.06.058.

PMID:
25239345
7.

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR.

J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.

PMID:
22311829
8.

Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications.

Verma V, Li J, Lin C.

Am J Clin Oncol. 2016 Jun;39(3):302-13. doi: 10.1097/COC.0000000000000278. Review.

PMID:
26950464
9.

Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.

Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Am Coll Surg. 2014 Jul;219(1):111-20. doi: 10.1016/j.jamcollsurg.2014.02.023. Epub 2014 Mar 13.

PMID:
24856952
10.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

11.

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.

Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, Li T, Ciocca V, Cooper H, Hoffman JP.

Am J Surg. 2008 Mar;195(3):318-21. doi: 10.1016/j.amjsurg.2007.12.017.

PMID:
18308038
12.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
13.

A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.

Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, Vollmer CM Jr.

HPB (Oxford). 2013 Jan;15(1):49-60. doi: 10.1111/j.1477-2574.2012.00571.x. Epub 2012 Sep 24.

14.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

15.

Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.

Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, Falconi M.

Am J Surg. 2012 Feb;203(2):132-9. doi: 10.1016/j.amjsurg.2011.03.008. Epub 2011 Aug 6.

PMID:
21824596
16.

Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.

Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, Werner J, B├╝chler MW.

Br J Surg. 2016 Nov;103(12):1683-1694. doi: 10.1002/bjs.10221. Epub 2016 Sep 30.

PMID:
27686238
17.

Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP).

Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, Wolf RF, Aloia TA, Hansen PD.

HPB (Oxford). 2014 Apr;16(4):350-6. doi: 10.1111/hpb.12141. Epub 2013 Sep 24.

18.

Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.

Glazer ES, Rashid OM, Pimiento JM, Hodul PJ, Malafa MP.

Surgery. 2016 Nov;160(5):1288-1293. doi: 10.1016/j.surg.2016.04.039. Epub 2016 Jul 20.

PMID:
27450715
19.

Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.

Greer SE, Pipas JM, Sutton JE, Zaki BI, Tsapakos M, Colacchio TA, Gibson JJ, Wiener DC, Ripple GH, Barth RJ Jr.

J Am Coll Surg. 2008 Mar;206(3):451-7. doi: 10.1016/j.jamcollsurg.2007.10.002. Epub 2007 Dec 27.

PMID:
18308215
20.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638

Supplemental Content

Support Center